Degenerative OsteoarthritisPheno4U PilotNCT05302934
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
An observational study of Degenerative Osteoarthritis and Rheumatoid Arthritis, run by Aesculap AG at 4 sites in 2 countries.
Trial summary
Prospective, multinational pilot study for evaluation of the Pheno4U data platform in Total Knee Arthroplasty (TKA) patients Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy
- What is being tested?
- Pheno4U
- Type of treatment
- Medical device
- How many people
- 600 participants
- Where
- 4 sitesin 2 countries
- Study dates
- 28 Sep 2022to Mar 2028
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients will be recruited consecutively. No selection besides the inclusion and exclusion criteria will take place. Four different TKA implant systems can be used within the study: Columbus, E.motion, Enduro and VEGA according to the instructions for use.
Who may be able to join
- Patient undergoing a total knee arthroplasty with a B. Braun knee implant system
- Signed written informed consent
- Patient's willingness \& ability to use the "BPMpathway"sensor
- Patient's willingness \& ability to use the "4Patient" application
Who cannot join
- Patient age < 18 years
- Patient not willing to participate at the further follow-up
- Pregnancy
- If intraoperatively an implant from a different manufacturer is used, the study patient has to be excluded from the study.
Trial locations and contacts
4 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
4 sites in 2 countries
Germany3 sites, 3 recruiting
- Not yet recruiting
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, 01307
Jörg Lützner, Prof. Dr., joerg.luetzner@uniklinikum-dresden.de
Jörg Lützner, Prof. Dr.
- Recruiting
Waldkliniken Eisenberg
Eisenberg, Thuringia, 07607
Georg Matziolis, Prof. Dr., G.Matziolis@waldkliniken-eisenberg.de
Georg Matziolis, Prof. Dr.
- Recruiting
Vincentius Krankenhaus
Konstanz, Baden-Wurttemberg, 78464
Gunnar B Ochs, Prof. Dr., gunnar.ochs@glkn.de
Gunnar B Ochs, Prof. Dr.
United Kingdom1 site, 1 recruiting
- Not yet recruiting
Nottingham University Hospital NHS Trust
Nottingham, NG7 2UH
Khosrow Sehat, Khosrow.Sehat@nuh.nhs.uk
Khosrow Sehat
About this study
Official title: Prospective, Multinational Pilot Study for Evaluation of the PHENO4U Data Platform in Total Knee Arthroplasty Patients
Prospective, multinational pilot study for evaluation of the Pheno4U data platform in Total Knee Arthroplasty (TKA) patients
Read the detailed description
The study will collect data for each patient receiving an Aesculap Total Knee Arthroplasty (TKA) implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies.
The products under investigation will be used in routine clinical practice and according to the Instructions for Use (IFU). Data obtained in routine clinical use will be collected in the Pheno4U data platform. In addition, patients are expected to answer questionnaires about their health status. Furthermore, patients are asked to use the so called "BPMpathway" sensor and application in order to measure the active Range of Motion (ROM). The sensor can also be used for pre- and postoperative training .
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy, Chronic Instability of Knee, Stiffness of Knee, Deformity Knee
- Being tested
- Pheno4U
- Keywords
- bi-condylar knee replacement, severe knee joint conditions, patient reported outcome
- Medical subject headings
- Joint Diseases, Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pheno4UDevice
Also called Total Knee Arthroplasty
Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
| Study group | Role | What they receive |
|---|---|---|
| Pheno4U | The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies. Receives: Device: Pheno4U |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of any unknown risks or side effects in Total Knee Arthroplasty by using sensors and patient apps
The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies
Measured: up to 12 months postoperatively
Secondary outcomes (7)
Change of Knee Injury and Osteoarthritis Outcome score
The Patient self-assessed Injury and Knee Osteoarthritis Outcome Scores (KOOS) is a joint-specific instrument: The KOOS evaluates both short-term and long-term consequences of knee injury. It holds 42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). The score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems.
Measured: 2 weeks prior to surgery, 6 weeks postoperatively and approximately 1 year after surgery
Change of Hospital for Special Surgery (HSS) Knee Surgery Expectations Survey
The Hospital for Special Surgery (HSS) Knee Surgery Expectations Survey is a 17 item questionnaire. The survey is comprised of five different categories of expectations: pain, walking, psychological state, essential activities and non-essential activities. The responses range from ''very important'' (score: 1) to ''this does not imply to me'' (score: 5). The total summed raw score ranges from 0 to 76 and the transformed score [ = (raw score/76)×100] ranges from 0 to 100. Higher scores indicate expecting more improvement for more items.
Measured: 2 weeks prior to surgery, 6 weeks postoperatively and approximately 1 year after surgery
Change of Pain
Information on pain is collected by the so called "painDETECT" questionnaire, a self-reported screening tool for the identification of neuropathic pain. The questionnaire contains seven weighted sensory descriptors, one item relating to spatial pain characteristics and one item relating to temporal characteristics. A total score ranging from -1 to 38 can be calculated. The total score is divided into three categories (unlikely neuropathic pain (<13), unclear (13-18), likely neuropathic pain (>18)).
Measured: 2 weeks prior to surgery, 6 weeks postoperatively and approximately 1 year after surgery
Patient satisfaction
Based on a single question 9 months after surgery patients are asked to grade their level of satisfaction with the methodology and rehabilitation procedure. They can choose between "very dissatisfied", "dissatisfied", "satisfied" or "very satisfied".
Measured: approximately 9 months after surgery
Net Promoter Score
The Net Promoter Score (NPS) is an index ranging from -100 to 100 that measures the willingness of patients to recommend the treatment to others. It is used as a proxy for gauging the patient's overall satisfaction with a treatment. Patients are surveyed on one single question. They are asked to rate on an 11-point scale the likelihood of recommending the treatment to a friend or colleague. "On a scale of 0 to 10, how likely are you to recommend the same treatment to a friend or a colleague?" Based on their rating, customers are then classified in 3 categories: detractors, passives and promoters. 'Detractors' gave a score lower or equal to 6. 'Passives' gave a score of 7 or 8. 'Promoters' answered 9 or 10. The NPS is determined by subtracting the percentage of customers who are detractors from the percentage who are promoters.
Measured: approximately 12 months after surgery
Change of Depression, Anxiety and Stress Scale - 21 Items
The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. Each of the three DASS-21 scales contains 7 items with a four point rating scale (ranging 0 - 3 points) for each item. The depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest / involvement, anhedonia and inertia. The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The stress scale assesses difficulty relaxing, nervous arousal, and being easily upset / agitated, irritable / over-reactive and impatient. The total score is calculated by summing the scores for the relevant items, the minimum score is 0 points, the maximum score for each section is 21. A lower score represents less depression, anxiety and stress.
Measured: 1 week prior to surgery and 2 weeks postoperatively
Development of Active Range of Motion
The active Range of Motion (ROM) is measured with the BPMpathway sensor and application 3 times per day for the entire duration of usage of the sensor. In general, the sensor is used for pre- and postoperative training. Patients are expected to use the sensor from pre-op consultation up to 3 month after surgery.
Measured: up to 3 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2022
- Study start28 Sep 2022
- Primary completionJun 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Degenerative OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aesculap AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jörg Lützner, Prof. Dr., Principal investigator, Universitätsklinikum Carl Gustav Carus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05302934
- Sponsor's protocol ID
- AAG-O-H-2113
- Acronym
- Pheno4U Pilot
- Status last verified
- Feb 2026
- First submitted
- 22 Mar 2022
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No